My diagnosis is a LPL non-WM. A high kappa light chain count caused a peripheral neuropathy with profound lower leg weakness and that was my presenting symptom. Treatment was 4 months of bendamustine-rituximab followed by two additional months of rituximab. The bendamustine was stopped 2 months early since my kappa light chains had plateaued at a 90% decrease and I was starting to have some bothersome side effects.
Both of my oncologists at different facilities agreed that I should be on maintenance rituximab every 2 months for 2 years. The reasons were one - that the kappa light chain level had not reached what is considered a normal level (though it is debatable what is a normal level for a 77 year old), and two, the severity of the presenting neuropathy. (The neuropathy greatly improved within 2 months of treatment.)
Of course I did some searching through the web for the pros and cons of maintenance therapy and could find convincing arguments on both sides. I decided that I was happy with the treatment plan so far and would stay with what both docs were recommending.
I hope my experience might be helpful to you.